Last reviewed · How we verify
Epithelium-Off Riboflavin
Epithelium-off riboflavin uses ultraviolet A light activation of riboflavin to create reactive oxygen species that cross-link corneal collagen, strengthening the cornea.
Epithelium-off riboflavin uses ultraviolet A light activation of riboflavin to create reactive oxygen species that cross-link corneal collagen, strengthening the cornea. Used for Keratoconus (progressive), Post-refractive surgery corneal ectasia, Corneal weakening/ectasia.
At a glance
| Generic name | Epithelium-Off Riboflavin |
|---|---|
| Also known as | Vitamin B2 |
| Sponsor | Crowd Health Research, LTD |
| Drug class | Corneal cross-linking agent |
| Target | Corneal collagen (indirect via riboflavin photosensitization) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
This is a corneal cross-linking procedure used to halt or slow the progression of keratoconus and corneal ectasia. Riboflavin (vitamin B2) is applied topically to the cornea after removal of the epithelium, then activated by UVA light, generating free radicals that form covalent bonds between collagen molecules. This increases corneal biomechanical stability and halts disease progression.
Approved indications
- Keratoconus (progressive)
- Post-refractive surgery corneal ectasia
- Corneal weakening/ectasia
Common side effects
- Corneal haze
- Temporary vision reduction
- Epithelial defect healing delay
- Dry eye
Key clinical trials
- Epi-on CuRV and Epi-off aCXL Protocols in the Management of Keratoconus
- Accelerated Corneal Collagen Crosslinking Protocols (NA)
- Topo-Pachymetric Customized Accelerated Epi-On Vs Accelerated Epi-Off Corneal Cross Linking in Keratoconus Management (NA)
- Photorefractive Intrastromal Crosslinking (PiXL) for the Treatment of Progressive Keratoconus (NA)
- Three Different Cross-linking Protocols for Treatment of Pediatric Keratoconus (NA)
- Cross-linking as Treatment in Infectious Keratitis (NA)
- The Effects of Corneal Collagen Cross-linking (PHASE3)
- Study of Demarcation Line Depth in Transepithelial Versus Epithelium-off Accelerated Cross-linking (AXL) in Keratocouns (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epithelium-Off Riboflavin CI brief — competitive landscape report
- Epithelium-Off Riboflavin updates RSS · CI watch RSS
- Crowd Health Research, LTD portfolio CI